Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 2/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14586836 | 0.86 | TSHR (0.35) | SMN1; SMN2LMNAGAAMAPTTSHR | |
| SCHEMBL14722574 | 0.79 | CCR1 (0.40) | SMN1; SMN2LMNAGAAMAPTTSHR | |
| SCHEMBL22001919 | 0.79 | KDM4E (0.37) | HTR7HTR1ADRD2HTR2A | |
| SCHEMBL30984900 | 0.79 | KDM4E (0.37) | HTR7HTR1ADRD2HTR2A | |
| SCHEMBL1411656 | 0.79 | — | — | |
| SCHEMBL23176941 | 0.78 | APP (0.31) | — | |
| SCHEMBL16416755 | 0.78 | MAPT (0.37) | SMN1; SMN2LMNAGAAMAPTTSHR | |
| SCHEMBL13622417 | 0.78 | SMN1; SMN2 (0.31) | SMN1; SMN2LMNAGAAMAPTTSHR | |
| SCHEMBL14722925 | 0.76 | KCNH2 (0.33) | — | |
| SCHEMBL877018 | 0.75 | CCR1 (0.34) | SMN1; SMN2LMNAGAAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8536209-B2 | Aminotriazole derivatives as ALX agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-17 | — | — | US | disclosed |
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| EP-2619181-A1 | NOVEL MICROBIOCIDES | Syngenta Participations AG (CH) | 2013-07-31 | — | — | EP | disclosed |
| CN-101903353-B | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS LTD | 2013-04-10 | — | — | CN | disclosed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION (CH) | 2010-12-30 | — | — | US | disclosed |
| CN-101903353-A | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-12-01 | — | — | CN | disclosed |
| CN-101903378-A | Aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-12-01 | — | — | CN | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| EP-2225231-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-7615636-B2 | Ruthenium complexes with tridentate heterocyclic ligand and dye-sensitized solar cells using the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2009-11-10 | — | — | US | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077990-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20080114174-A1 | RUTHENIUM COMPLEXES WITH TRIDENTATE HETEROCYCLIC LIGAND AND DYE-SENSITIZED SOLAR CELLS USING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | SMN1; SMN2 4778/4885LMNA 3986/4885GAA 1211/4885 |
| US-20080114174-A1 | RUTHENIUM COMPLEXES WITH TRIDENTATE HETEROCYCLIC LIGAND AND DYE-SENSITIZED SOLAR CELLS USING THE SAME | HRH3, HRH1, HRH4 | SMN1; SMN2 4885/4885LMNA 4017/4885GAA 4576/4885 |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | SMN1; SMN2 4612/4885LMNA 4005/4885GAA 2359/4885 |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ADORA1, ADORA3, TBXA2R | SMN1; SMN2 4596/4885LMNA 3975/4885GAA 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.